Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (December 2013)

36 slides from Sorrento Therapeutics's investor presentation, December 2013

  1. Slide 1: Sorrento Therapeutics: Next-Generation Cancer Therapeutics

    Sorrento Therapeutics Next-Generation Cancer Therapeutics December 2013

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement NASDAQ: SRNE This presentation contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements regarding expectations, beliefs or intentions regarding our business, technologies and products

  3. Slide 3: Management Team

    Management Team Henry Ji, Ph.D. • Inventor of G-MAB® Technology President & CEO, and Director • President & CEO of Stratagene Genomics • VP of CombiMatrix and Stratagene Vuong Trieu, Ph.D. • Founder and CEO of IgDraSol Chief Scientific Officer, and Director • Co-inventor of IP covering Abraxane® • I

  4. Slide 4: Investment Highlights

    Investment Highlights Late Stage Oncology Drug with Exclusive US and EU Rights • Addresses multi-billion dollar paclitaxel market • Abbreviated regulatory pathway (“bioequivalence”) for approval Cynviloq™ • Bioequivalence registration trial in 2014 (study direct costs ~ $5M) • Product launch expecte

  5. Slide 5: Sorrento's Next-Generation Cancer Therapeutics

    Sorrento’s Next-Generation Cancer Therapeutics G-MAB® • High-diversity human Ab library • Lead mAb programs include PD-L1, PD-1, and CCR2 Cynviloq™ TUMOR • FTO and no stacking royalties  Next-generation Abraxane® • Bioequivalence (BE) pathway for approval • Efficacy demonstrated • US and EU rights

  6. Slide 6: Pipeline

    Pipeline INDICATION Metastatic Breast Cancer } 505(b)(2) Bioequivalence 1H 2014 1H 2015 Non-Small Cell Lung Cancer Cynviloq™ Pancreatic Cancer (BE* or sNDA) Bladder Cancer (sNDA) Multiple Ovarian Cancer (sNDA) PHASE 1 PHASE 2 RTX Refractory Pain in Cancer Patients In progress 1H 2015 Strategic INDIC

  7. Slide 7: Lead Product Opportunity Cynviloq

    Lead Product Opportunity Cynviloq™ 7

  8. Slide 8: Cynviloq is the 3rd Generation Paclitaxel Therapy

    Cynviloq is the 3rd Generation Paclitaxel Therapy Maximum Peak Generation Formulation Tolerated Dose Product Sales 1st Cremophor EL Taxol® excipient: 175 mg/m2 ~ $1.6B (WW in 2000) paclitaxel Polyoxyethylated castor oil 2nd Biological polymer: 260 mg/m2 Est. >$1.7B* (US) Abraxane® Mean size Donor-de

  9. Slide 9: Cynviloq is a High Value Proposition

    Cynviloq is a High Value Proposition 1. Exclusive US and EU Rights 2. Cynviloq efficacy demonstrated in Phase 2 and Phase 3 studies a. Approved and marketed under brand name Genexol-PM in S. Korea 3. FDA concurred a. Available data support pursuing 505(b)(2) regulatory pathway b. Bioequivalence (BE)

  10. Slide 10: Clinical Efficacy & Safety Summary

    Clinical Efficacy & Safety Summary Total number of patients across all trials: 1,260 Phase 1: Trials established higher MTD in US - Dana Farber Cancer Inst, Russia, & S. Korea (total n=80)  >300 mg/m2 (q3w) vs. 175 mg/m2 (Taxol; weekly) and 275 mg/m2 (Abraxane; q3w) Phase 2: Completed trials in MBC

  11. Slide 11: Equivalent Pharmacokinetics in Mice

    Equivalent Pharmacokinetics in Mice Abraxane Cynviloq AUCinf (h*ng/ Drug HL (h) T max (h) Vz (mL/kg) Cl (mL/h/kg) mL) Abraxane 2.99 0.08 61561.33 2103.71 487.32 Cynviloq 2.83 0.08 58151.31 2103.58 515.90 IV bolus at 30 mg/kg; n = 3 Data on file 11

  12. Slide 12: Comparable Pharmacokinetics in Human

    Comparable Pharmacokinetics in Human Data from 2 separate studies (3 h infusion, 135 mg/m2 dose, n=3) Abraxane data from: Nurad K. Ibrahim, Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel. Clinical Cancer Research 2002;8:1038

  13. Slide 13: Simulated PK Parameters Supportive of BE

    Simulated PK Parameters Supportive of BE: Cynviloq vs. Abraxane Comparison of mean non-compartmental pharmacokinetic parameters of Cynviloq (T) and Abraxane (260 mg/m2) at 30 min infusion time: Cmax Ratio AUCinf Ratio (ng/mL) Cmax(T)/Cmax(R) (ng*h/mL) AUCinf(T)/AUCinf(R) Cynviloq 19486 22198 (Simula

  14. Slide 14: Bioequivalence = Efficient Pathway to Market

    Bioequivalence = Efficient Pathway to Market • Bioequivalence registration study in breast cancer patients (2014) - 12 months of duration (including patient recruitment) - Direct trial cost ~$5M Key Parameters*: Abraxane® Cynviloq™ • Dose: 260 mg/m2 Cycle 1 (50 patients) (50 patients) • Infusion tim

  15. Slide 15: Cynviloq Advantages

    Cynviloq Advantages Cynviloq Cynviloq™ Abraxane® Taxol® Advantage Maximum Tolerated Dose Potential for >300 260 175 (mg/m2) higher efficacy Rapid reconstitution: Convenience for busy no foaming concerns ● ● practices and pharmacies No donor-derived human serum albumin (HSA) ● ● No viral / prion conc

  16. Slide 16: Cynviloq Market Opportunity

    Cynviloq Market Opportunity ~70,000 patients treated with paclitaxel-based regimen in 1st line 100,000 # of Patients Treated in 1st line (US Only; 2012) 90,000 Other regimens ~55,000 patients with paclitaxel as 1st line therapy 80,000 PAC+ treated in MBC, NSCLC & OC 70,000 60,000 50,000 15,903 PC pa

  17. Slide 17: Potential to Expand Label Indications – 2nd Line Bladder Cancer

    Potential to Expand Label Indications – For Example: 2nd Line Bladder Cancer Cynviloq Best Supportive Care Phase 2 (Korea)* Phase 2 (Japan) **/ Phase 3 (EU)*** 260-300 mg/m2 q3w n=23** / n=108*** n=34# Overall Response Rate (ORR) 21% - / 0%*** Progression Free Survival 2.7 M - / 1.5 M*** Overall Sur

  18. Slide 18: Next Steps for Cynviloq

    Next Steps for Cynviloq 1. Bioequivalence (BE) trial: 2014 2. NDA filing: 2015 3. Approval: 2016 a. MBC and NSCLC b. Future Abraxane indications (Pancreatic cancer and Melanoma) 4. Product launch for MBC and NSCLC: 2016 5. sNDA planning for label expansion into Bladder and Ovarian cancers Bioequival

  19. Slide 19: Expanded Clinical Pipeline with Multiple Opportunities: RTX

    Expanded Clinical Pipeline with Multiple Opportunities RTX 19

  20. Slide 20: Resiniferatoxin (RTX): Non-opiate Drug Candidate for Cancer Pain

    Resiniferatoxin (RTX): Non-opiate Drug Candidate for Treating Cancer Pain Cross section of spinal cord after treatment* Pharmacology: RTX induces apoptosis of TRPV1- Ultra potent agonist of the TRPV1 receptor expressing afferent nerves. • < 2 pM TRPV1 receptor binding “ADC”-like killing, but no anti

  21. Slide 21: Single Injection Addresses Cancer Pain in Dogs

    Single Injection Addresses Cancer Pain in Dogs n=18 Observational Pain Score  Single intrathecal injection VAS (0 to 100 mm)  Permanent ablation of nerves  Attractive Therapeutic Effect (p < 0.0001 for all time points)  All subjects responded  Personality & mood of animals visibly improved n=18

  22. Slide 22: Next Steps for Dual Pathway of RTX Development

    Next Steps for Dual Pathway of RTX Development 2014 1. Intractable cancer pain clinical Phase 1/2 trial (intrathecal injection); n~40 patients 2. Phase 1/2 trial for intraganglionic injection (osteosarcoma); n~15 patients (under NIH CRADA) ~3 years for clinical development 22

  23. Slide 23: Pre-IND Immunotherapy Programs G-MAB ADC

    Pre-IND Immunotherapy Programs G-MAB® ADC 23

  24. Slide 24: G-MAB: Library of Therapeutic Antibodies

    G-MAB®: Library of Therapeutic Antibodies • Proprietary technology • Very high library diversity: - RNA amplification used for 2.1 x 1016 distinct antibodies library generation - Freedom-To-Operate • Fully human antibodies • No stacking royalties • High successful screening hit rate Most Difficult T

  25. Slide 25: Anti-PD-L1 mAbs Exhibit Potent Activity

    Anti-PD-L1 mAbs Exhibit Potent Activity Immune Modulation* Tumor Mouse Model** Tumor Growth Inhibition (%) *** T Cell Activation (%) IFN-γ (pg/mL) IL-2 (pg/mL) Day Competitor mAb Sorrento mAb * mAbs @ 0.05 mg/mL ** xenograft model using H1975 human NSCLC cells; % inhibition relative to control mAb t

  26. Slide 26: Potent Antibody against Difficult GPCR Target

    Potent Antibody against Difficult GPCR Target* 3.5 Cell Binding mAb (EC50 – nM) Sorrento 0.17 3 Competitor 21 2.5 Disease Score** 2 Untreated PBS 1.5 Sorrento D1 mAb therapeutic 1 0.5 0 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Days After Disease Induction * Sorre

  27. Slide 27: Antibody Drug Conjugates (ADC)

    Antibody Drug Conjugates (ADC) Key Components: 1. Target-specific internalizing antibody 2. Potent cytotoxic prodrugs 3. Linker and conjugation chemistries Drug released in CANCER CELL 27

  28. Slide 28: Proprietary Toxin Potency Higher than DM1

    Proprietary Toxin Potency Higher than DM1 SKBR3 (Breast Cancer Cell Line) Sorrento toxin 1 (K-lock) Sorrento toxin 2 (K-lock) >15x higher DM1 (NHS) potency MMAE (C-lock) MMAE (maleimide) cleavable MC-vc-PAB linker 28

  29. Slide 29: K-lock Conjugation Enables Homogeneous ADCs

    K-lock Conjugation Enables Homogeneous ADCs Current industry standard chemistry 2 Sorrento’s proprietary 1 K-lock chemistry 3 0 purified Purified 2 ADC Sorrento’s homogenous ADC 29

  30. Slide 30: Irreversible C-lock-stabilized ADCs

    Irreversible C-lock-stabilized ADCs Maleimide conjugation Current industry  Destabilizes antibody structure standard  Reduced target specificity  Altered PK profile  Drug-antibody linkage not stable  Off-target drug effects Sorrento’s C-lock conjugation proprietary  Enhances ADC stability C-lo

  31. Slide 31: Proprietary ADC Screening and Optimization Panels

    Proprietary ADC Screening and Optimization Panels n n n n n n n n n n n n n • linkers n n n • conjugation n n n n n n n n n n n n n n n n n n n n n Payload pool Chemistry 20 panel 50 panel (up to) ADCs consist of many moving parts. Identification of optimal linker, conjugation chemistry and drug pay

  32. Slide 32: G-MAB and ADC Pipeline

    G-MAB® and ADC Pipeline PD-L1 (STI-A100X) 1H 2015 PD-1 (STI-A110X) 2H 2015 Multiple VEGFR2-ADC (STI-A0168) 2H 2015 ONCOLOGY c-Met (STI-A060X) ADC ErbB3 ADC Strategic (STI-A050X) EGFR (STI-A020X) ADC Partnership CCR2 (STI-B020X) 1H 2016 ONCOLOGY / CXCR5 (STI-A120X) ADC INFLAMMATION (GPCR) CXCR4 (STI-

  33. Slide 33: Positioned to Become Oncology Leader

    Positioned to Become Oncology Leader Cynviloq™ RTX G-MAB® ADC 33

  34. Slide 34: Small Molecule Oncology Drug, Antibody Library and ADC Company Valuations

    Small Molecule Oncology Drug, Antibody Library and ADC Company Valuations Company Small Molecule Antibody Targeted Mkt Cap* Oncology Drug Platform Drug Delivery Puma: PBYI MBC (Phase 3) ~$1.2B Pre-revenue Clovis: CLVS NSCLC, MBC (Phase 1) ~$1.6B Pre-revenue MorphoSys: MOR.DE Antibody ~$1.6B Pre-reve

  35. Slide 35: Investment Highlights

    Investment Highlights Late Stage Oncology Drug with Exclusive US and EU Rights • Addresses multi-billion dollar paclitaxel market • Abbreviated regulatory pathway (“bioequivalence”) for approval Cynviloq™ • Bioequivalence registration trial in 2014 (study direct costs ~ $5M) • Product launch expecte

  36. Slide 36: Sorrento Therapeutics: Contact

    Sorrento Therapeutics Next-Generation Cancer Therapeutics Contact: Henry Ji President and CEO hji@sorrentotherapeutics.com (858) 668-6923

Sorrento Therapeutics — Investor Presentation (December 2013) on 6ix